Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01224262 | A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 | PHASE1 | COMPLETED | 152 | — | — | Sep 1, 2010 | Dec 1, 2011 | Mar 1, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Fluzone + 0.45 mg LIQ001 | EXPERIMENTAL | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg) |
| Fluzone + 1.8 mg LIQ001 | EXPERIMENTAL | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg) |
| Fluzone | ACTIVE_COMPARATOR | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) |
| Name | Type | Description |
|---|---|---|
| Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) | BIOLOGICAL | A single vaccination of Fluzone alone |
| LIQ001 (0.45mg) | BIOLOGICAL | A single vaccination of 0.45 mg LIQ001 |
| LIQ001 (1.8mg) | BIOLOGICAL | A single vaccination of 1.8 mg LIQ001 |
Inclusion Criteria: * Age 18 to 49 years (Cohort 1) and age 65 or above (Cohort 2) * For subjects 18 to 49 years of age: in good health as determined by medical history, physical examination, and the clinical judgment of the Principal Investigator (PI) * For subjects 65 years of age and older: in s...